Emily
Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883298/
Kroenke E, Ankar A, Malani Shukla N. Refractory MOG-Associated Demyelinating Disease in a Pediatric Patient. Child Neurol Open. 2022 Feb 25;9:2329048X221079093. doi: 10.1177/2329048X221079093. PMID: 35237705; PMCID: PMC8883298.
Abstract
Background: MOG antibody associated demyelinating disease (MOGAD) is a newly described autoimmune disorder that presents with monophasic or multiphasic demyelination in children. Case: We report a case of MOGAD that was refractory to current treatment algorithms and required rapid escalation of immunotherapy to achieve disease control. Conclusion: This case helps to further expand the phenotype of MOGAD and emphasizes the need to consider MOGAD in patients presenting with focal neurologic deficits, altered mental status, and/or seizures.
Keywords: MOGAD, demyelinating disease, pediatric
...
Discussion
MOGAD is a newly described autoimmune disease whose phenotype continues to expand with new patient cases. While initially the existence of positive serum MOG antibodies was thought to be a biological marker for MS, it is now widely agreed that the presence of MOG antibodies typically suggests a non-MS course.[SUP] 5 [/SUP] The detection of MOG antibodies is most commonly associated with a multitude of demyelinating conditions including ADEM, relapsing optic neuritis (ON), NMOSD, MDEM, and relapsing transverse myelitis (TM); however, MOGAD can also present as autoimmune encephalitis, with altered mental status, seizures, and mainly cortical involvement. Recently, a leukodystrophy-like phenotype has also been described.[SUP]6,7...[/SUP]
Kroenke E, Ankar A, Malani Shukla N. Refractory MOG-Associated Demyelinating Disease in a Pediatric Patient. Child Neurol Open. 2022 Feb 25;9:2329048X221079093. doi: 10.1177/2329048X221079093. PMID: 35237705; PMCID: PMC8883298.
Abstract
Background: MOG antibody associated demyelinating disease (MOGAD) is a newly described autoimmune disorder that presents with monophasic or multiphasic demyelination in children. Case: We report a case of MOGAD that was refractory to current treatment algorithms and required rapid escalation of immunotherapy to achieve disease control. Conclusion: This case helps to further expand the phenotype of MOGAD and emphasizes the need to consider MOGAD in patients presenting with focal neurologic deficits, altered mental status, and/or seizures.
Keywords: MOGAD, demyelinating disease, pediatric
...
Discussion
MOGAD is a newly described autoimmune disease whose phenotype continues to expand with new patient cases. While initially the existence of positive serum MOG antibodies was thought to be a biological marker for MS, it is now widely agreed that the presence of MOG antibodies typically suggests a non-MS course.[SUP] 5 [/SUP] The detection of MOG antibodies is most commonly associated with a multitude of demyelinating conditions including ADEM, relapsing optic neuritis (ON), NMOSD, MDEM, and relapsing transverse myelitis (TM); however, MOGAD can also present as autoimmune encephalitis, with altered mental status, seizures, and mainly cortical involvement. Recently, a leukodystrophy-like phenotype has also been described.[SUP]6,7...[/SUP]